Section Arrow
Quote
STRO.NASDAQ
- Sutro Biopharma Inc.
Quotes are at least 15-min delayed:2026/07/10 06:41 EDT
Pre Market
Last
 30.01
+0.02 (+0.07%)
Bid
25.1
Ask
30.59
High 30.59 
Low 30.01 
Volume 51 
Regular Hours (Closed)
Last
 29.99
-1.85 (-5.81%)
Day High 
32.71 
Prev. Close
31.84 
1-M High
34.05 
Volume 
248.24K 
Bid
25.1
Ask
30.59
Day Low
29.78 
Open
32 
1-M Low
24.3927 
Market Cap 
527.60M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 31.19 
20-SMA 29.81 
50-SMA 31.84 
52-W High 43.85 
52-W Low 0.8294 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-16.35/-4.92
Enterprise Value
535.49M
Balance Sheet
Book Value Per Share
-4.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
102.48M
Operating Revenue Per Share
3.43
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VRAXVirax Biolabs Group Limited6.36+3.18+100.00%-- 
Pre Market 5.2448 -1.1152 -17.53%
EVGNEvogene Ltd.0.5+0.0859+20.74%-- 
Pre Market 0.4801 -0.0199 -3.98%
RXRXRecursion Pharmaceuticals3.76+0.04+1.08%-- 
Pre Market 3.72 -0.04 -1.06%
IONSIonis Pharmaceuticals64.27-20.19-23.90%-- 
Pre Market 64.42 +0.15 +0.23%
BBIOBridgeBio Pharma90.17+11.84+15.12%-- 
Pre Market 90.09 -0.08 -0.09%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.